Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6–8, 2014
Gespeichert in:
| Veröffentlicht in: | Cancer Immunology, Immunotherapy Immunotherapy, 2015-07, Vol.64 (7), p.923-930 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 930 |
|---|---|
| container_issue | 7 |
| container_start_page | 923 |
| container_title | Cancer Immunology, Immunotherapy |
| container_volume | 64 |
| creator | Kloke, Björn-Philipp Mahr, Andrea Jabulowsky, Robert A. Kutscher, Sarah Rae, Richard Britten, Cedrik M. |
| description | |
| doi_str_mv | 10.1007/s00262-014-1643-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11028691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1691598671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c574t-bf217489a9bbc2707ed22c2d80c865f6fe793b46fa529860178086419b5665b23</originalsourceid><addsrcrecordid>eNqFkstuEzEUhi1ERUPhAdggS2yKlAHb4ysbhCJoK7ViU9aWx_FkXDJ2sD2Vwop3YMfj8SQ4pFQFgVj5cv7znYt-AJ5g9AIjJF5mhAgnDcK0wZy2jbgHZpi29UcyfB_MUEtRIxCih-Bhzlf1QpBSD8AhYYxKpNoZ-LYwwboE_ThOIZbBJbPZQmMH765dhl1y5mMZUpxWA8zFlCm_gpiUAZoQJrOGo3PFhxWMPazJ0OQcrTfFxwD7mKD9G_14cXZx-XwOL4wPn-fwxKXRhO3uvYX8-5evcg5JnekROOjNOrvHN-cR-PDu7eXitDl_f3K2eHPeWCZoabqeYEGlMqrrLBFIuCUhliwlspKznvdOqLajvDeMKMkRFhJJTrHqGOesI-0ReL3nbqZudEvrQklmrTfJjyZtdTRe_x4JftCreK0xRkRyhSvh-IaQ4qfJ5aJHn61br01wccoaC6SwYBKT_0srj9U2xY767A_pVZxSqKv4qSKEylZVFd6rbIo5J9ffNo6R3rlE712i60b1ziVa1Jyndye-zfhliyoge0GuobBy6U7pf1J_AOu8x44</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1691224839</pqid></control><display><type>article</type><title>Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6–8, 2014</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><creator>Kloke, Björn-Philipp ; Mahr, Andrea ; Jabulowsky, Robert A. ; Kutscher, Sarah ; Rae, Richard ; Britten, Cedrik M.</creator><creatorcontrib>Kloke, Björn-Philipp ; Mahr, Andrea ; Jabulowsky, Robert A. ; Kutscher, Sarah ; Rae, Richard ; Britten, Cedrik M.</creatorcontrib><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-014-1643-7</identifier><identifier>PMID: 25548093</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antibodies ; Antibodies, Monoclonal - therapeutic use ; Cancer ; Cancer Research ; Cancer Vaccines - therapeutic use ; Clinical trials ; CTLA-4 Antigen - immunology ; Cytotoxicity ; Dimensional analysis ; Germany ; Humans ; Immunology ; Immunotherapy ; Immunotherapy - methods ; Ipilimumab ; Ligands ; Lymphocytes ; Medicine ; Medicine & Public Health ; Meeting Report ; Melanoma ; Neoplasms - immunology ; Neoplasms - therapy ; Oncology ; Patients ; R&D ; Research & development ; Success ; T-Lymphocytes, Cytotoxic - immunology ; Tumor Microenvironment - immunology</subject><ispartof>Cancer Immunology, Immunotherapy, 2015-07, Vol.64 (7), p.923-930</ispartof><rights>Springer-Verlag Berlin Heidelberg 2014</rights><rights>Springer-Verlag Berlin Heidelberg 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c574t-bf217489a9bbc2707ed22c2d80c865f6fe793b46fa529860178086419b5665b23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11028691/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11028691/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,309,310,314,725,778,782,787,788,883,23917,23918,25127,27911,27912,41475,42544,51306,53778,53780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25548093$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kloke, Björn-Philipp</creatorcontrib><creatorcontrib>Mahr, Andrea</creatorcontrib><creatorcontrib>Jabulowsky, Robert A.</creatorcontrib><creatorcontrib>Kutscher, Sarah</creatorcontrib><creatorcontrib>Rae, Richard</creatorcontrib><creatorcontrib>Britten, Cedrik M.</creatorcontrib><title>Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6–8, 2014</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><addtitle>Cancer Immunol Immunother</addtitle><subject>Antibodies</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Clinical trials</subject><subject>CTLA-4 Antigen - immunology</subject><subject>Cytotoxicity</subject><subject>Dimensional analysis</subject><subject>Germany</subject><subject>Humans</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Ipilimumab</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meeting Report</subject><subject>Melanoma</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Oncology</subject><subject>Patients</subject><subject>R&D</subject><subject>Research & development</subject><subject>Success</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Tumor Microenvironment - immunology</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkstuEzEUhi1ERUPhAdggS2yKlAHb4ysbhCJoK7ViU9aWx_FkXDJ2sD2Vwop3YMfj8SQ4pFQFgVj5cv7znYt-AJ5g9AIjJF5mhAgnDcK0wZy2jbgHZpi29UcyfB_MUEtRIxCih-Bhzlf1QpBSD8AhYYxKpNoZ-LYwwboE_ThOIZbBJbPZQmMH765dhl1y5mMZUpxWA8zFlCm_gpiUAZoQJrOGo3PFhxWMPazJ0OQcrTfFxwD7mKD9G_14cXZx-XwOL4wPn-fwxKXRhO3uvYX8-5evcg5JnekROOjNOrvHN-cR-PDu7eXitDl_f3K2eHPeWCZoabqeYEGlMqrrLBFIuCUhliwlspKznvdOqLajvDeMKMkRFhJJTrHqGOesI-0ReL3nbqZudEvrQklmrTfJjyZtdTRe_x4JftCreK0xRkRyhSvh-IaQ4qfJ5aJHn61br01wccoaC6SwYBKT_0srj9U2xY767A_pVZxSqKv4qSKEylZVFd6rbIo5J9ffNo6R3rlE712i60b1ziVa1Jyndye-zfhliyoge0GuobBy6U7pf1J_AOu8x44</recordid><startdate>20150701</startdate><enddate>20150701</enddate><creator>Kloke, Björn-Philipp</creator><creator>Mahr, Andrea</creator><creator>Jabulowsky, Robert A.</creator><creator>Kutscher, Sarah</creator><creator>Rae, Richard</creator><creator>Britten, Cedrik M.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150701</creationdate><title>Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6–8, 2014</title><author>Kloke, Björn-Philipp ; Mahr, Andrea ; Jabulowsky, Robert A. ; Kutscher, Sarah ; Rae, Richard ; Britten, Cedrik M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c574t-bf217489a9bbc2707ed22c2d80c865f6fe793b46fa529860178086419b5665b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antibodies</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Clinical trials</topic><topic>CTLA-4 Antigen - immunology</topic><topic>Cytotoxicity</topic><topic>Dimensional analysis</topic><topic>Germany</topic><topic>Humans</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Ipilimumab</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meeting Report</topic><topic>Melanoma</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Oncology</topic><topic>Patients</topic><topic>R&D</topic><topic>Research & development</topic><topic>Success</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Tumor Microenvironment - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kloke, Björn-Philipp</creatorcontrib><creatorcontrib>Mahr, Andrea</creatorcontrib><creatorcontrib>Jabulowsky, Robert A.</creatorcontrib><creatorcontrib>Kutscher, Sarah</creatorcontrib><creatorcontrib>Rae, Richard</creatorcontrib><creatorcontrib>Britten, Cedrik M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kloke, Björn-Philipp</au><au>Mahr, Andrea</au><au>Jabulowsky, Robert A.</au><au>Kutscher, Sarah</au><au>Rae, Richard</au><au>Britten, Cedrik M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6–8, 2014</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><addtitle>Cancer Immunol Immunother</addtitle><date>2015-07-01</date><risdate>2015</risdate><volume>64</volume><issue>7</issue><spage>923</spage><epage>930</epage><pages>923-930</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>25548093</pmid><doi>10.1007/s00262-014-1643-7</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-7004 |
| ispartof | Cancer Immunology, Immunotherapy, 2015-07, Vol.64 (7), p.923-930 |
| issn | 0340-7004 1432-0851 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11028691 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; PubMed Central |
| subjects | Antibodies Antibodies, Monoclonal - therapeutic use Cancer Cancer Research Cancer Vaccines - therapeutic use Clinical trials CTLA-4 Antigen - immunology Cytotoxicity Dimensional analysis Germany Humans Immunology Immunotherapy Immunotherapy - methods Ipilimumab Ligands Lymphocytes Medicine Medicine & Public Health Meeting Report Melanoma Neoplasms - immunology Neoplasms - therapy Oncology Patients R&D Research & development Success T-Lymphocytes, Cytotoxic - immunology Tumor Microenvironment - immunology |
| title | Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6–8, 2014 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T13%3A27%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%20immunotherapy%20achieves%20breakthrough%20status:%2012th%20annual%20meeting%20of%20the%20association%20for%20cancer%20immunotherapy%20(CIMT),%20Mainz,%20Germany,%20May%206%E2%80%938,%202014&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=Kloke,%20Bj%C3%B6rn-Philipp&rft.date=2015-07-01&rft.volume=64&rft.issue=7&rft.spage=923&rft.epage=930&rft.pages=923-930&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/s00262-014-1643-7&rft_dat=%3Cproquest_pubme%3E1691598671%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1691224839&rft_id=info:pmid/25548093&rfr_iscdi=true |